TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06788990: FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Sponsor: Bicara Therapeutics · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 650 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,340,028

Rescue Site Savings

+$2,874,564

Unlock Full NCT06788990 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06788990 Rescue Dossier →